Cargando…
The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674975/ https://www.ncbi.nlm.nih.gov/pubmed/34256026 http://dx.doi.org/10.1016/j.amjmed.2021.06.014 |
| _version_ | 1784615784204468224 |
|---|---|
| author | Eiser, Arnold R. |
| author_facet | Eiser, Arnold R. |
| author_sort | Eiser, Arnold R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8674975 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86749752021-12-16 The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point Eiser, Arnold R. Am J Med Commentary Elsevier Inc. 2021-12 2021-07-12 /pmc/articles/PMC8674975/ /pubmed/34256026 http://dx.doi.org/10.1016/j.amjmed.2021.06.014 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Commentary Eiser, Arnold R. The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point |
| title | The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point |
| title_full | The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point |
| title_fullStr | The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point |
| title_full_unstemmed | The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point |
| title_short | The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point |
| title_sort | current state of pharma and the fda: approval of a dementia drug as a case in point |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674975/ https://www.ncbi.nlm.nih.gov/pubmed/34256026 http://dx.doi.org/10.1016/j.amjmed.2021.06.014 |
| work_keys_str_mv | AT eiserarnoldr thecurrentstateofpharmaandthefdaapprovalofadementiadrugasacaseinpoint AT eiserarnoldr currentstateofpharmaandthefdaapprovalofadementiadrugasacaseinpoint |